- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
Live Investor Briefing
Prescient Therapeutics (ASX: PTX)
Monday, 31st March 12pm (AEDT)
Please join Prescient CEO James McDonnell for an investor briefing.
James will discuss:
- How PTX-100’s Phase 1b results – which exceeded expectations and existing drugs – provide a strong basis as we move into Phase 2 clinical trials.
- How the FDA’s Orphan Drug Designation and its Investigational New Drug approval, along with future possible designations, could lead to a registrational study approach fast-tracking PTX-100 into commercialisation – with a A$1bn+ market in the US alone.
- Why PTX-100 in T Cell Lymphomas is just one indication of a much broader RAS family inhibitor approach, which has potential applications for 22% of cancer cases world-wide.
This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.
Can’t make this time, register to receive the replay.
Attend the session
What is a 708 investor?By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services to Prescient Therapeutics Limited and has been engaged by them to manage their investor communications including managing this offer and may receive fees for its services.
Featured Speaker
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing significantly to the company’s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
Dr Rebecca Lim
Senior Vice President of Scientific Affairs
Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.
Receive email updates
What is a 708 investor?By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.